Tempus ai inc TEM.US 總覽分析
TEM 投資分析
看多重點:
- 價值≥4
- 股利≥2
分析結論
公司發布財報數據季度不足,尚無法提供評分
TEM 近期報酬表現
11.85%
Tempus ai inc
10.92%
同產業平均
0.39%
S&P500
與 TEM 同產業的標的表現
股票代碼 | 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 加入追蹤 |
---|---|---|---|---|---|---|---|
RYTM | Rhythm pharmaceuticals inc | 4 分 | 4 分 | 5 分 | 2 分 | 1 分 | |
KRYS | Krystal biotech inc | 4 分 | 2 分 | 4 分 | 2 分 | 1 分 | |
RGNX | Regenxbio inc | 2 分 | 2 分 | 4 分 | 3 分 | 1 分 | |
SNDX | Syndax pharmaceuticals inc | 2 分 | 3 分 | 2 分 | 4 分 | 1 分 | |
CYTK | Cytokinetics, inc. | 3 分 | 2 分 | 4 分 | 4 分 | 1 分 |
- RYTM Rhythm pharmaceuticals inc價值 4 分趨勢 4 分波段 5 分籌碼 2 分股利 1 分查看更多
TEM 公司資訊
Tempus Ai Inc. Tempus AI, Inc. is a technology company. The Company provides next generation diagnostics across multiple disease areas, with technology capabilities, harnessing the data and analytics to help personalize medicine. The Company's product lines include genomics, data, and artificial intelligence applications (AI). Its genomics product line leverages its laboratories to provide next generation sequencing, diagnostics, polymerase chain reaction (PCR), profiling, molecular genotyping, and other anatomic and molecular pathology testing. The Company's AI applications are focused on developing and providing diagnostics that are algorithmic in nature, implementing new software as a medical device, and building and deploying clinical decision support tools. Its primary product of AI applications is Next, an AI platform that leverages machine learning to apply an intelligent layer onto routinely generated data to proactively identify and minimize care gaps for oncology and cardiology patients.